ASTRO 2017: Gene Aberrations in Patients With Lung Adenocarcinomas Undergoing SBRT
Posted: Monday, October 9, 2017
Results from the first series to quantify genetic mutations in patients with early-stage lung adenocarcinomas undergoing stereotactic body radiation therapy (SBRT) were presented at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 1158). Richard John Cassidy III, MD, of the Winship Cancer Institute of Emory, Atlanta, and colleagues found patients showing the KRAS mutation seemed to have worse local recurrence after SBRT. In addition, the presence of the proto-oncogene MET was correlated with worse regional and metastatic recurrence.
In a pool of 242 patients with early-stage lung cancer, 98 patients (40.5%) with lung adenocarcinomas were identified. About half of these patients underwent genetic testing. KRAS mutation and MET amplification were seen in 20% and 17.8% of patients, respectively. Other genetic aberrations included EGFR (15.6%), p53 (15.6%), ALK rearrangement (8.9%), HER2 (6.7%), SMAD4 (4.4%), BRAF (2.2%), STK11 (2.2%), RET rearrangement (2.2%), and PTEN (2.2%).
After 1 year, control rates were lower for patients with KRAS mutation (63.5%) compared with patients with KRAS wild-type (96%). Those with MET amplification demonstrated lower rates of regional and metastatic control (38.1% and 68.6%, respectively) than did those with MET wild-type disease (87.5% and 85.4%, respectively).
Investigators concluded that their study results need to be researched further in a prospective setting.
